Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Chain Bridge I Market Cap
The Chain Bridge I (CBRG) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered CBRG. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for CBRG is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned CBRG 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Chain Bridge I to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CBRG. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CBRG.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2022
Staff Count
0
Country
United States
Sector/Industry
Financial Services/Shell Companies
CEO
Mr. Andrew Cohen
Market Cap
$77.5M
In 2023, CBRG generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CBRG's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - MCAP MediaWire
Summary - Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid therapeutics, has released a new investor deck as of July 30, 2024.
Why It Matters - Phytanix Bio's release of an investor deck signals potential growth in the cannabinoid pharmaceutical sector, attracting investor interest and possibly impacting stock valuations.
Mon, 22 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Chain Bridge I is set to acquire Phytanix Bio, forming a new public company that will focus on developing advanced cannabinoid and cannabinoid-like medicines.
Why It Matters - The acquisition signals growth potential in the cannabinoid sector, potentially increasing market valuation and attracting investor interest in innovative biotech solutions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
